62071-40-3

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
4-(TETRAHYDRO-PYRAN-4-YL)-PHENYLAMINE serves as a key building block in the synthesis of various pharmaceutical and agrochemical compounds. It is utilized for its ability to contribute to the structural and functional diversity of these compounds, enhancing their therapeutic or pesticidal properties.
Used in Organic and Medicinal Chemistry:
In the realm of organic and medicinal chemistry, 4-(TETRAHYDRO-PYRAN-4-YL)-PHENYLAMINE is employed as a ligand in transition metal-catalyzed cross-coupling reactions. Its use in these reactions is crucial for the formation of new carbon-carbon or carbon-heteroatom bonds, which are essential in the synthesis of complex organic molecules with potential medicinal applications.
Used in Drug Development:
4-(TETRAHYDRO-PYRAN-4-YL)-PHENYLAMINE is also of interest in drug development due to its potential biological activity. It is being investigated for its potential use as a drug candidate, indicating its possible role in the treatment or management of various diseases or conditions, pending further research and development.

Upstream product

• 1039053-21-8 C₁₁H₁₃NO 

Downstream Products

• 1227864-28-9 4-[(3,5-difluorobenzyl)amino]-6-{[4-(tetrahydro-2H-pyran-4-yl)phenyl]amino}pyridine-3-carboxyamide 
• 1374211-70-7 6-(4-(tetrahydro-2H-pyran-4-yl)phenylamino)-4-(tetrahydro-2H-pyran-4-ylamino)nicotinamide 
• 1374215-18-5 C₁₇H₁₈ClN₃O₂ 
• 1374215-19-6 C₁₇H₁₈ClN₃O₂ 
• 1374215-16-3 C₁₇H₁₆ClN₃O 
• 1312479-26-7 4,4,5,5-tetramethyl-2-(4-(tetrahydro-2H-pyran-4-yl)phenyl)-1,3,2-dioxaborolane 
• 811828-76-9 4-(4-bromophenyl)-tetrahydro-2H-pyran 

Relevant academic research and scientific papers

P2Y1 receptor antagonists as novel antithrombotic agents

The P2Y1 and P2Y12 purinergic receptors are responsible for mediating adenosine diphosphate (ADP) dependent platelet aggregation. Evidence from P2Y1 knockout studies as well as from nucleotide-based small molecule P2Y1 antagonists has suggested that the antagonism of this receptor may offer a novel and effective method for the treatment of thrombotic disorders. Herein, we report the identification and optimization of a series of non-nucleotide P2Y1 antagonists that are potent and orally bioavailable.

Novel p-(4-tetrahydropyranyl)-phenoxy-compounds

Novel pyranic derivatives of the formula STR1 wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms and cations of alkali metals, alkaline earth metals, aluminum, amines and ammonium R1 and R2 are